

07.30	Registration & Coffee	
08.20	Opening Speech by Leonard Sachs, Managing Director, Sachs Associates	
08.30	"Neurotherapeutics: Progress During an Era of Peace and Tranquility" by Harry Tracy, President, NI Research	
08.50	<p><b>Pharma Neurotherapeutics Pipeline: "The Challenges Ahead"</b>            Chaired by:            Ginger Johnson, CEO, Defined Health, a Cello Health business            Panelists:            Darryle Schoepp, VP Neuroscience Research, Early Development and Discovery Sciences, Merck and Co.            Guy Seabrook, Vice President &amp; Global Lead, Neuroscience External Innovation, Johnson &amp; Johnson Innovation            Jennifer Laird, Senior Director, Search &amp; Evaluation, External R&amp;D, Eli Lilly and Co.            Michael Ehlers, Executive Vice President, R&amp;D, Biogen            Michael Gold, VP Neuroscience Development, AbbVie, Inc.</p>	
09.30	<p><b>Partnering &amp; DealMaking Panel</b>            Co-Chaired by:            Bruce Leuchter, Managing Director, PJT Partners            Steve Dickman, CEO, CBT Advisors            Panelists:            Charles Bailey, Head of Search &amp; Evaluation, Neurosciences, Global Business Development &amp; Licensing, Novartis            Don Frail, SVP, Research, External Science, and Non-clinical and Translational Sciences, Allergan            Johannes Grosse, Director, CNS pharmacology and collaboration, Takeda California, Inc.            Laura Corradini, Deputy Global Head, BD &amp; Licensing CNS, Boehringer Ingelheim Pharma GmbH &amp; Co. KG            Shafique Virani, CEO in Residence/Global Head – Neuroscience, Ophthalmology &amp; Rare Disease Partnering, BridgeBio, LLC</p>	
10.10	Coffee Break	
10.25	<p><b>Advances in Alzheimer's and other Cognitive Disorders Panel</b>            Chaired by:            Ryan Westphal, Sr. Director, Neuroscience Search &amp; Evaluation, Eli Lilly and Co.            Panelists:            Carlos Buesa, CEO, Oryzon Genomics SA            Eugene Williams, Executive Chairman, ProMIS™ Neurosciences, Inc.            Isaac Veinbergs, Head of External Innovation, Neurosciences, Strategy &amp; Business Development, Sanofi            Jonathan Lewis, Executive Chairman and CEO, Samus Therapeutics, Inc.            Konrad Glund, CEO, Probiodrug AG            Susan Catalano, Founder and CSO, Cognition Therapeutics, Inc.</p>	<p><b>PR Companies Track A</b></p>
		<p>10.25 Marinus Pharmaceuticals, Inc. [NASDAQ: MRNS]</p>
11.05	<p><b>Introductory Speech to Neuropsychiatry and Pain Management Panel</b>            by Randall Stevens, CMO, Centrexion Therapeutics Corp.</p>	<p>10.45 Nexstim Plc [NXTMH:FH]</p>
		<p>11.05 Cavion</p>
11.25	<p><b>New Approaches to Neuropsychiatry and Pain Management Panel</b>            Co-Chaired by:            John Renger, Vice President, Head of Clinical Research and Translational Medicine, Purdue Pharma L.P.            Raghuram Selvaraju, Managing Director, H.C. Wainwright &amp; Co.            Panelists:            Deborah Rathjen, CEO &amp; Managing Director, Bionomics Ltd.            Jonathan Javitt, CEO, NeuroRx, Inc.            Karl Johe, Chairman and Chief Scientific Officer, Neuralstem, Inc.            Michael Scherz, Founder &amp; CEO, Metys Pharmaceuticals AG            Seth Lederman, CEO, Tonix Pharmaceuticals Holding Corp.</p>	<p>11.25 Oryzon Genomics SA [BME:ORY]</p>
		<p>11.45 Probiodrug AG [AMS:PBD]</p>
		<p>12.05 ProMIS™ Neurosciences, Inc. [PMN:CN]</p>
12.10	<p><b>Medical Cannabis in Neuroscience Panel</b>            Chaired by:            Michael Farley, Director, Valor Management SA            Panelists:            Andrea Small-Howard, CSO, GB Sciences, Inc.            Avtar Dhillon, MD, Executive Chairman, Emerald Health Therapeutics, Inc.            Cam Battley, Executive VP, Aurora Cannabis, Inc.            Catherine Jacobson, Director of Clinical Research, Tilray</p>	<p>12.25 Click Therapeutics, Inc.</p>
12.45	Networking Lunch	

12.45	Networking Lunch				
13.30	"TBA" by Daniel Alkon, President and CSO, Neurotrope Bioscience, Inc.				
13.50	<b>Innovative Approaches to Parkinson's and Other Movement Disorders Panel</b> Co-Chaired by: Kiran Reddy, Venture Partner, Clarus Ventures, LLC Murali Gopalakrishnan, Senior Director, Search & Evaluation Neuroscience, AbbVie, Inc. Panelists: Andrew Hindman, Chief Business Development Officer, Acorda Therapeutics, Inc. Brian Fiske, SVP, Research Programs, Michael J. Fox Foundation Damien McDevitt, SVP, Corporate Development, ACADIA Pharmaceuticals, Inc. Jesse Cedarbaum, VP, Early Clinical Development, Biogen Kees Been, CEO, Lysosomal Therapeutics Kenneth Rhodes, CSO, Yumanity Therapeutics	PR Companies Track B			
		13.50	Bonti		
		14.00	Cenna Biosciences, Inc.		
		14.10	Invisio Pharmaceuticals		
		14.20	K-PAX Pharmaceuticals, Inc.		
14.35	<b>Current Trends in NeuroTech &amp; Market Opportunities Panel</b> Co-Chaired by: David Cassak, Editor-in-Chief, The MedTech Strategist Stephen Levin, Managing Partner, The MedTech Strategist Panelists: David Klein, CEO, Click Therapeutics, Inc. Martin Jamieson, Chairman and CEO, Nexstim Plc Mylea Charvat, CEO and Co-Founder, Savonix, Inc. Kevin Wasserstein, Founder and CEO, Neurotechnology Innovation Translator Steven Powell, CEO, Cambridge Cognition	PR Companies Track C			
		14.30	Origenis GmbH		
		14.40	Sense Diagnostics, LLC		
		14.40	Metys Pharmaceuticals AG		
15.10	PR Companies Track E	PR Companies Track D			
		15.00	Aurora Cannabis, Inc. [TSE: ACB]	15.00	AZTherapies, Inc.
		15.20	Emerald Health Therapeutics, Inc. [CVE: EMH]	15.20	Cognition Therapeutics, Inc.
		15.40	[Reserved]	15.40	KalGene Pharmaceuticals, Inc.
				15.50	[Reserved]
15.50	Bionomics Ltd. - [ASX:BNO]				
16.10	NeuroRx, Inc.				
16.30	Coffee Break				
16.45	<b>Investor Roundtable</b> Chaired by: Beth Jacobs, Managing Partner, Excellentia Global Partners Panelists: Barbara Tate, Venture Partner, SV Life Sciences Danny Talati, Director, New Business Development, Fortress Biotech, Inc. Jamil Beg, Principal, SAM Ventures Jay Olson, Research Analyst, Oppenheimer & Co., Inc. Kristen Kosofsky, Senior Managing Director, Hercules Technology Growth Capital, Inc. Manuel Lopez Figueroa, Venture Partner, Bay City Capital				
17.30	Networking Reception				
18.30	End of the 1 <sup>st</sup> NTI Forum				

## Supported by:

